
    
      The continued clinical experience addendum is a prospective, multi-center, non-randomized,
      interventional study to evaluate the safety and effectiveness of the Harmony TPV system. All
      implanted subjects will receive the Harmony TPV 22 or Harmony mTPV 25 device. This phase
      allows up to 45 subjects implanted with TPV 22 in the United States and Canada, and up to 84
      subjects implanted with mTPV 25 in the United States.
    
  